SCHEMBL149368

SCHEMBL149368

Nc1nc(=O)n([C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O2)cc1Br

nearest known ligand 0.62

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
POLG P54098 2/20 0.55
POLB P06746 3/20 0.54
P2RY2 P41231 5/20 0.53
P2RY4 P51582 3/20 0.53
P2RY6 Q15077 3/20 0.53
DTYMK P23919 2/20 0.47
NT5E P21589 1/20 0.45
TRPM2 O94759 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416602 1.00 POLG (0.55) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL15810673 1.00 POLG (0.55) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL3470530 0.90 POLB (0.55) POLB
SCHEMBL20906735 0.90 POLG (0.56) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL2981336 0.90 POLG (0.56) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL2981333 0.90 POLG (0.56) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL25492503 0.89 POLG (0.70) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL20906738 0.89 POLG (0.55) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL20906736 0.89 POLG (0.55) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL8409011 0.89 POLG (0.70) POLGPOLBP2RY2P2RY4P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1017 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320485-A1 METHODS AND COMPOSITIONS FOR DETECTING GENOMIC METHYLATION ILLUMINA INC (US) 2025-10-16 US claimed
US-20250210148-A1 METHOD OF PRODUCING DATA-ENCODED NUCLEIC ACID AND NUCLEIC ACID PRODUCED BY THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2025-06-26 US claimed
US-20250051840-A1 DETECTION OF GENETIC AND EPIGENETIC INFORMATION IN A SINGLE WORKFLOW FOUNDATION MEDICINE, INC. (US) 2025-02-13 US claimed
EP-4481057-A1 SAMPLE PREPARATION METHODS USING MODIFIED BASES FOR RAPID IDENTIFICATION AND SEQUENCING Depixus (FR) 2024-12-25 EP claimed
EP-4457357-A2 DETECTION OF GENETIC AND EPIGENETIC INFORMATION IN A SINGLE WORKFLOW Foundation Medicine, Inc. (US) 2024-11-06 EP claimed
CN-118541493-A Detection of genetic and epigenetic information in a single workflow 基金会医学公司 2024-08-23 CN claimed
EP-4392555-A2 METHODS AND COMPOSITIONS FOR DETECTING GENOMIC METHYLATION Illumina, Inc. (US) 2024-07-03 EP claimed
WO-2023129965-A2 DETECTION OF GENETIC AND EPIGENETIC INFORMATION IN A SINGLE WORKFLOW FOUNDATION MEDICINE, INC. (US) 2023-07-06 WO claimed
WO-2023028478-A2 METHODS AND COMPOSITIONS FOR DETECTING GENOMIC METHYLATION ILLUMINA, INC. (US) 2023-03-02 WO claimed
US-10799602-B2 Method for increasing expression of RNA-encoded proteins CUREVAC AG (DE) 2020-10-13 US claimed
US-10293060-B2 Method for increasing expression of RNA-encoded proteins CUREVAC AG (DE) 2019-05-21 US claimed
US-20190100784-A1 RNA ANALYSIS BY TOTAL HYDROLYSIS CureVac SE (DE) 2019-04-04 US claimed
EP-3423595-A1 RNA ANALYSIS BY TOTAL HYDROLYSIS CureVac AG (DE) 2019-01-09 EP claimed
US-20030039976-A1 Methods for base counting PE CORPORATION (NY) 2003-02-27 US claimed
EP-4747380-A1 MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE CRISPR Therapeutics AG (CH) 2026-05-27 EP disclosed
WO-2026103936-A1 CHEMICALLY MODIFIED CIRCULAR RNA MOLECULE, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海元码智药生物技术有限公司 2026-05-21 WO disclosed
US-20260137769-A1 NUCLEIC ACID MOLECULES AND USES THEREOF CureVac SE (DE) 2026-05-21 US disclosed
WO-2005094421-A2 METHODS FOR CONCURRENT IDENTIFICATION AND QUANTIFICATION OF AN UNKNOWN BIOAGENT ISIS PHARMACEUTICALS, INC. (US) 2005-10-13 WO disclosed
WO-2005089128-A2 RAPID IDENTIFICATION OF MICROBIAL AGENTS ISIS PHARMACEUTICALS, INC. (US) 2005-09-29 WO disclosed
US-20030039976-A1 Methods for base counting PE CORPORATION (NY) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10293060-B2 Method for increasing expression of RNA-encoded proteins STING1, UPF1, CUTA POLG 397/4885POLB 273/4885P2RY2 4010/4885
US-10799602-B2 Method for increasing expression of RNA-encoded proteins STING1, UPF1, CUTA POLG 397/4885POLB 273/4885P2RY2 4010/4885
US-20260137769-A1 NUCLEIC ACID MOLECULES AND USES THEREOF RNMT, RNGTT, NSUN3 POLG 1112/4885POLB 733/4885P2RY2 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.